Bracket Names Jeff Kinell as CEO

Wayne, PA (October 6, 2014) – Bracket, a leading clinical trial specialty services provider, today announced the addition of Jeffrey W. Kinell as Chief Executive Officer and as a new member of its Board of Directors.

Jeff brings more than 30 years of experience to Bracket, primarily in leadership positions in growth oriented, health services and pharmaceutical outsourcing firms. Most recently, Jeff was CEO of CRI Lifetree, a mid-size specialized research organization focused in early phase clinical development. During his five-year tenure, Jeff oversaw the firm’s transformation into a scientifically driven organization offering highly specialized capabilities across multiple therapeutic areas that are in high demand by both pharmaceutical and biotech companies.

“I’ve been fortunate to work closely with Bracket and many of its customers over the years,” said Jeff. “I’ve seen first-hand how this team’s commitment to scientific leadership, technological innovation and operational excellence makes it one of the most exciting and innovative companies in the specialty clinical arena. I’m honored and privileged to join Bracket, and to help build an even more successful future for the organization, our clients, and for the countless individuals whose lives are improved by medications we help advance.”

“Jeff intimately understands the pharma/biotech specialty clinical space and the unique demands of clinical trials in multiple therapeutic areas and across multiple study phases,” said David G. Daniel, M.D., Bracket Senior Vice President and Chief Medical Director. “This, combined with his broad experience across science, technology, and operations, makes him the perfect fit for Bracket, especially as we continue to innovate and grow as an independent, privately held company.”

Jim Primerano, Bracket Senior Vice President and General Manager for the eClinical group added, “Jeff’s experience and leadership will be invaluable to our existing team, and I know that Bracket and our clients are going to benefit greatly from his years of providing dynamic solutions to the biopharmaceutical market. He has a true commitment to innovative products, and a unique perspective from actually dealing with the practical challenges of implementing technology solutions in a clinical environment. He sees the obvious benefits of adopting technology solutions in clinical trials to create efficiencies and improve quality.”

Annette Larkin